Stock CAPR CAPRICOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.41 USD +5.05% Intraday chart for Capricor Therapeutics, Inc. +7.98% +10.63%
Apr. 24 Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug MT
Apr. 24 Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy CI

Evolution of the average Target Price on Capricor Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

91e2e1c5f4abbe4.7ofrrSXt1Q3mpt-LRYOnOvgmszgsAQ_f4oATSv868ac.19LfwkzUjTSOzZfSB9zkDchp4UFcYjqcsdp-KZZtweqt0JOfbp2_OY-e7w~50e46972584bdf0a22044a5f0b54445d

Analyst Recommendations on Capricor Therapeutics, Inc.

HC Wainwright Raises Price Target on Capricor Therapeutics to $40 From $18, Keeps Buy Rating MT
Ladenburg Thalmann Starts Capricor Therapeutics at Buy With $15 Price Target MT
HC Wainwright Adjusts Capricor Therapeutics' Price Target to $18 From $14, Reiterates Buy Rating MT
CAPRICOR THERAPEUTICS : HC Wainwright Boosts Price Target on Capricor Therapeutics to $14 From $9, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.41 USD
Average target price
21 USD
Spread / Average Target
+288.17%
High Price Target
40 USD
Spread / Highest target
+639.37%
Low Price Target
8 USD
Spread / Lowest Target
+47.87%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Capricor Therapeutics, Inc.

HC Wainwright
Ladenburg Thalmann

Ratings for Capricor Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. Consensus Capricor Therapeutics, Inc.